Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Circulating Tumor Cells, Circulating Tumor DNA and Other Blood-based Prognostic Scores in Pancreatic Ductal Adenocarcinoma - Mini-Review

M. Liberko, K. Kolostova, A. Szabo, R. Gurlich, M. Oliverius, R. Soumarova

. 2021 ; 35 (1) : 31-39. [pub] -

Language English Country Greece

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc21019545

Pancreatic ductal adenocarcinoma represents a disease with increasing incidence. Its prognosis is the worst among all malignancies despite the aggressive combined multimodal treatment across all stages. In metastatic disease, median survival is approximatelly one year. The mainstay of treatment is chemotherapy (neo/adjuvant, palliative) and in selected subgroups of patients even radiotherapy. Nevertheless, nowadays there are very few prognostic and/or predictive biomarkers available that can be used to identify and better stratify patients based on risk to tailored treatment. Potentially, promising areas of research are circulating tumor cells and circulating tumor DNA, which can be easily obtained from peripheral blood - so called liquid biopsy. They may serve as a tool to assess response to applied treatment, and to detect the emergence of treatment-resistant clones or early disease relapse. Moreover, their study may allow identification of potentially tumor-specific alterations, which may serve as target structures for targeted (tailored) therapy. Alternatively, different prognostic indexes/scores calculated by analysis of selected parameters of blood and/or biochemistry can be used to better stratify patients based on risk and better predict prognosis. The aim of this mini-review is to provide a basic overview of the current state of the art in this area and its potential significance for clinical practice.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019545
003      
CZ-PrNML
005      
20210830101134.0
007      
ta
008      
210728s2021 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.12229 $2 doi
035    __
$a (PubMed)33402447
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Liberko, Marian $u Department of Radiotherapy and Oncology, University Hospital Kralovske Vinohorady, Prague, Czech Republic; marian.liberko@fnkv.cz $u Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
245    10
$a Circulating Tumor Cells, Circulating Tumor DNA and Other Blood-based Prognostic Scores in Pancreatic Ductal Adenocarcinoma - Mini-Review / $c M. Liberko, K. Kolostova, A. Szabo, R. Gurlich, M. Oliverius, R. Soumarova
520    9_
$a Pancreatic ductal adenocarcinoma represents a disease with increasing incidence. Its prognosis is the worst among all malignancies despite the aggressive combined multimodal treatment across all stages. In metastatic disease, median survival is approximatelly one year. The mainstay of treatment is chemotherapy (neo/adjuvant, palliative) and in selected subgroups of patients even radiotherapy. Nevertheless, nowadays there are very few prognostic and/or predictive biomarkers available that can be used to identify and better stratify patients based on risk to tailored treatment. Potentially, promising areas of research are circulating tumor cells and circulating tumor DNA, which can be easily obtained from peripheral blood - so called liquid biopsy. They may serve as a tool to assess response to applied treatment, and to detect the emergence of treatment-resistant clones or early disease relapse. Moreover, their study may allow identification of potentially tumor-specific alterations, which may serve as target structures for targeted (tailored) therapy. Alternatively, different prognostic indexes/scores calculated by analysis of selected parameters of blood and/or biochemistry can be used to better stratify patients based on risk and better predict prognosis. The aim of this mini-review is to provide a basic overview of the current state of the art in this area and its potential significance for clinical practice.
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    12
$a duktální karcinom slinivky břišní $x diagnóza $x genetika $x terapie $7 D021441
650    12
$a cirkulující nádorová DNA $x genetika $7 D000074141
650    _2
$a lidé $7 D006801
650    _2
$a lokální recidiva nádoru $7 D009364
650    12
$a nádorové cirkulující buňky $7 D009360
650    12
$a nádory slinivky břišní $x diagnóza $x genetika $x terapie $7 D010190
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Kolostova, Katarina $u Department of Laboratory Genetics, Laboratory Diagnostics, University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Szabo, Arpad $u Department of Pathology, Third Faculty of Medicine, Charles University in Prague and University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Gurlich, Robert $u Department of General Surgery, University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Oliverius, Martin $u Department of General Surgery, University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Soumarova, Renata $u Department of Radiotherapy and Oncology, University Hospital Kralovske Vinohorady, Prague, Czech Republic $u Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
773    0_
$w MED00175831 $t In vivo (Athens, Greece) $x 1791-7549 $g Roč. 35, č. 1 (2021), s. 31-39
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33402447 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101134 $b ABA008
999    __
$a ok $b bmc $g 1690387 $s 1139991
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 35 $c 1 $d 31-39 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options